Micro Labs, Saptalis debut generic Riomet

Sandra Levy
Senior Editor
Sandra Levy profile picture

Micro Labs USA  and Saptalis Pharmaceuticals, are introducing Metformin oral solution.

"After the successful launch of Clobetasol topical solution, Micro Labs is once again very excited to collaborate with Saptalis on the second product launch within three months" said Ashok Jain, director of Micro Labs USA. “This is a testimony to our growing association and we look forward to additional launches in 2020.”

The product is the only generic of Sun Pharmaceutical’s Riomet and indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with Type 2 diabetes mellitus.

"Saptalis is proud to offer patients with diabetes a much-anticipated generic equivalent of Riomet oral solution. Metformin is considered the first line of treatment for managing Type 2 diabetes, and is the most widely prescribed oral medication for millions of patients. We are confident that the introduction of an affordable generic liquid formulation in two packaging sizes will help to expand the use of the medication in the growing patient segments with difficulty swallowing, including geriatric population. We value our partnership with Micro Labs and anticipate to strengthen it in the near future,” Polireddy Dondeti, Saptalis president and CEO said.

Riomet had a market value in 2019 of $15 million, according to IQVIA.